Characteristics of the 88 patients
| Characteristic . | No. patients . |
|---|---|
| Total number of patients | 88 |
| Sex (M:F) | 44:44 |
| Age at diagnosis, mo; median (range) | 5.0 (0.1-16.5) |
| WBC at diagnosis (× 109/L); median (range) | 18.0 (1.4-800) |
| Immunophenotype (%) | |
| B cell precursor | 75 (85) |
| T cell | 7 (8) |
| Null cell | 6 (7) |
| Cytogenetics (%) | |
| Normal | 17 (19) |
| Hyperdiploid | 20 (23) |
| t(4;11) | 7 (8) |
| t(9;22) | 4 (5) |
| Other cytogenetic abnormality | 31 (35) |
| Unknown | 9 (10) |
| Extramedullary disease (%) | |
| None | 48 (55) |
| At diagnosis | 8 (9) |
| Post diagnosis | 32 (36) |
| Age at transplantation, y; median (range) | 8.9 (0.5-17.7) |
| Duration of CR1,3-150 mo; median (range) | 30 (2-90) |
| Diagnosis to transplantation, mo; median (range) | 36 (5-151) |
| CR1 patients | 7 (5-51) |
| Phase of disease (%) | |
| CR1 | 10 (11) |
| CR2 | 34 (39) |
| CR3 | 10 (11) |
| Relapse | 34 (39) |
| CMV (%) | |
| (+) recipient/(±) donor | 31 (35) |
| (−) recipient/(+) donor | 20 (23) |
| (−) recipient/(−) donor | 37 (42) |
| Regimen (%) | |
| Cy + TBI 14.4 Gy | 84 (95) |
| Cy + TBI 15.75 Gy | 4 (5) |
| GVHD prophylaxis (%) | |
| CSP/MTX | 86 (98) |
| CSP/prednisone | 1 (1) |
| FK506/MTX | 1 (1) |
| Donor HLA (%) | |
| Match | 56 (64) |
| Mismatch at A or B | 15 (17) |
| Mismatch at DR/DRB1 | 17 (19) |
| Cells (× 108/kg); median (range) | 4.5 (0.7-46.2) |
| Characteristic . | No. patients . |
|---|---|
| Total number of patients | 88 |
| Sex (M:F) | 44:44 |
| Age at diagnosis, mo; median (range) | 5.0 (0.1-16.5) |
| WBC at diagnosis (× 109/L); median (range) | 18.0 (1.4-800) |
| Immunophenotype (%) | |
| B cell precursor | 75 (85) |
| T cell | 7 (8) |
| Null cell | 6 (7) |
| Cytogenetics (%) | |
| Normal | 17 (19) |
| Hyperdiploid | 20 (23) |
| t(4;11) | 7 (8) |
| t(9;22) | 4 (5) |
| Other cytogenetic abnormality | 31 (35) |
| Unknown | 9 (10) |
| Extramedullary disease (%) | |
| None | 48 (55) |
| At diagnosis | 8 (9) |
| Post diagnosis | 32 (36) |
| Age at transplantation, y; median (range) | 8.9 (0.5-17.7) |
| Duration of CR1,3-150 mo; median (range) | 30 (2-90) |
| Diagnosis to transplantation, mo; median (range) | 36 (5-151) |
| CR1 patients | 7 (5-51) |
| Phase of disease (%) | |
| CR1 | 10 (11) |
| CR2 | 34 (39) |
| CR3 | 10 (11) |
| Relapse | 34 (39) |
| CMV (%) | |
| (+) recipient/(±) donor | 31 (35) |
| (−) recipient/(+) donor | 20 (23) |
| (−) recipient/(−) donor | 37 (42) |
| Regimen (%) | |
| Cy + TBI 14.4 Gy | 84 (95) |
| Cy + TBI 15.75 Gy | 4 (5) |
| GVHD prophylaxis (%) | |
| CSP/MTX | 86 (98) |
| CSP/prednisone | 1 (1) |
| FK506/MTX | 1 (1) |
| Donor HLA (%) | |
| Match | 56 (64) |
| Mismatch at A or B | 15 (17) |
| Mismatch at DR/DRB1 | 17 (19) |
| Cells (× 108/kg); median (range) | 4.5 (0.7-46.2) |
CMV indicates cytomegalovirus; CR1, first complete remission; CR2, second complete remission; CSP, cyclosporine; Cy, cyclophosphamide; MTX, methotrexate; and TBI, total body irradiation.
Excludes patients in CR1 at time of transplantation.